

**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: Alberto Pappo, M.D.

Committee: Pediatric Subcommittee of the Oncologic Drugs Advisory Committee

Meeting Date: June 28-29, 2016

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: On June 28-29, 2016, information will be presented to the subcommittee to gauge interest in exploring potential pediatric development plans for five chemical entities including, tazemetostat, Loxo-101, and entrectinib. I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Contract/Grant	Epizyme, sponsor	\$0 – 50,000 per year
	Loxo Oncology, sponsor	\$50,001 – \$100,000 per year
	Loxo Oncology, potentially affected firm	\$50,001 – \$100,000 per year

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting sessions above. I understand that without public disclosure of these interests, I will not participate in the advisory committee sessions described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_6/27/2016\_\_\_\_\_  
Date